Skip to Primary Navigation

Skip to main content

Elanco fined $15m for Reg S-K misrepresentations

Multicolor files in a clinic drawer
Photo: Linda Raymond/Getty Images

Alexander Barzacanos

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Elanco’s use of sales incentives created misleading impressions of customer demand, the SEC stated.

Elanco, a veterinary pharmacology company, agreed to settle charges with the SEC over accusations that it made misleading statements about its revenue growth and user demand. The company will pay a $15m penalty without admitting or denying the charges.  

The SEC’s charges arise from deficiencies in Elanco’s

, , , , , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience